Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name ANRASSF1
   Synonyms RASSF1-AS1, ANRASSF1
   Region GRCh38_3:50337511-50338300    Sequence
   Ensembl ENSG00000281358
   RefSeq NR_109831
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name breast cancer
   ICD-0-3 C50  
   Methods RNA-seq, qPCR, RNAi, Western blot, RIP, ChIP, Cell proliferation assay etc.
   Sample cell lines (HeLa, MDA-MB-231, LNCaP and MCF-7)
   Expression Pattern up-regulated
   Function Description

ANRASSF1 endogenous expression is higher in breast and prostate tumor cell lines compared with non-tumor, and an opposite pattern is observed for RASSF1A. ANRASSF1 ectopic overexpression reduces RASSF1A abundance and increases the proliferation of HeLa cells, whereas ANRASSF1 silencing causes the opposite effects. These changes in ANRASSF1 levels do not affect the RASSF1C isoform abundance. ANRASSF1 overexpression causes a marked increase in both PRC2 occupancy and histone H3K27me3 repressive marks, specifically at the RASSF1A promoter region.

   Pubmed ID 23990798
   Year 2013
   Title The intronic long noncoding RNA ANRASSF1 recruits PRC2 to the RASSF1A promoter, reducing the expression of RASSF1A and increasing cell proliferation.
   External Links
   Links for  ANRASSF1 GenBank       HGNC       lncrnadb       Noncode
   Links for  breast cancer Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.